{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:29:24Z","timestamp":1785227364066,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Liaoning Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016807","name":"Natural Science Foundation of Shenyang Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.mtbio.2026.102819","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:08:17Z","timestamp":1768716497000},"page":"102819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["ROS-responsive transmembrane peptide-antibody conjugate eyedrops for the non-invasive treatment of choroidoretinopathy"],"prefix":"10.1016","volume":"37","author":[{"given":"Lihang","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3851-3804","authenticated-orcid":false,"given":"Tu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5470-1599","authenticated-orcid":false,"given":"Jin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1379-7669","authenticated-orcid":false,"given":"Xiaoli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruidong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.mtbio.2026.102819_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: a review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.mtbio.2026.102819_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.mtbio.2026.102819_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abq3104","article-title":"Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment","volume":"9","author":"Shen","year":"2023","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102819_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American academy of ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.mtbio.2026.102819_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American academy of ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.mtbio.2026.102819_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2020.02.028","article-title":"Reducing treatment burden in AMD","volume":"180","author":"Apte","year":"2020","journal-title":"Cell"},{"issue":"10436","key":"10.1016\/j.mtbio.2026.102819_bib7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(24)00428-8","article-title":"The promise of long-term treatment for neovascular age-related macular degeneration","volume":"403","author":"Rakoczy","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.mtbio.2026.102819_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ophtha.2023.12.033","article-title":"Risk of endophthalmitis based on cumulative number of Anti-VEGF intravitreal injections","volume":"131","author":"Israilevich","year":"2024","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.mtbio.2026.102819_bib9","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA ophthalmology"},{"issue":"10","key":"10.1016\/j.mtbio.2026.102819_bib10","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.mtbio.2026.102819_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115004","article-title":"Nanomaterial-based ophthalmic drug delivery","volume":"200","author":"Xie","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2026.102819_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2024.10.001","article-title":"Dasatinib and erianin co-loaded ion-responsive in-situ hydrogel for effective treatment of corneal neovascularization","volume":"376","author":"Lei","year":"2024","journal-title":"J. Contr. Release : Off. J. Contr. Release Soc."},{"key":"10.1016\/j.mtbio.2026.102819_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2023.07.028","article-title":"Selective drug delivery to the retinal cells: biological barriers and avenues","volume":"361","author":"Ramsay","year":"2023","journal-title":"J. Contr. Release : Off. J. Contr. Release Soc."},{"issue":"32","key":"10.1016\/j.mtbio.2026.102819_bib14","article-title":"Innovative nanotechnology in drug delivery systems for advanced treatment of posterior segment ocular diseases","volume":"11","author":"Wu","year":"2024","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.mtbio.2026.102819_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.aopr.2024.11.003","article-title":"Nano-based drug delivery systems for the treatment of non-infectious uveitis","volume":"5","author":"Wu","year":"2025","journal-title":"Adv. Ophthalmol. Pract. Res."},{"issue":"2","key":"10.1016\/j.mtbio.2026.102819_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17020185","article-title":"Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos","volume":"17","author":"Kristensen","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mtbio.2026.102819_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nnm.13.193","article-title":"Biological effects of tat cell-penetrating peptide: a multifunctional trojan horse?","volume":"9","author":"Lee","year":"2014","journal-title":"Nanomedicine"},{"issue":"7","key":"10.1016\/j.mtbio.2026.102819_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.01.040","article-title":"RNA-binding proteins and glycoRNAs form domains on the cell surface for cell-penetrating peptide entry","volume":"188","author":"Perr","year":"2025","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.mtbio.2026.102819_bib19","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1016\/j.ymthe.2024.08.022","article-title":"A small TAT-TrkB peptide prevents BDNF receptor cleavage and restores synaptic physiology in Alzheimer's disease","volume":"32","author":"Fonseca-Gomes","year":"2024","journal-title":"Mol. Ther. : J. Am. Soc. Gene Therapy"},{"issue":"1\u20133","key":"10.1016\/j.mtbio.2026.102819_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-3659(02)00352-8","article-title":"Cytoplasmic delivery and nuclear targeting of synthetic macromolecules","volume":"87","author":"Jensen","year":"2003","journal-title":"J. Contr. Release : Off. J. Contr. Release Soc."},{"key":"10.1016\/j.mtbio.2026.102819_bib21","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.2147\/IJN.S255546","article-title":"TAT-modified gold nanoparticles enhance the antitumor activity of PAD4 inhibitors","volume":"15","author":"Song","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.mtbio.2026.102819_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2022.123125","article-title":"Functionalised penetrating peptide-chondroitin sulphate-gold nanoparticles: synthesis, characterization, and applications as an anti-Alzheimer's disease drug","volume":"230","author":"Feng","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.mtbio.2026.102819_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121368","article-title":"Red-light-triggered self-destructive mesoporous silica nanoparticles for cascade-amplifying chemo-photodynamic therapy favoring antitumor immune responses","volume":"281","author":"Yang","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.mtbio.2026.102819_bib24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2023.07.055","article-title":"Challenges and strategies for ocular posterior diseases therapy via non-invasive advanced drug delivery","volume":"361","author":"Qi","year":"2023","journal-title":"J. Contr. Release : Off. J. Contr. Release Soc."},{"key":"10.1016\/j.mtbio.2026.102819_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jconrel.2022.05.009","article-title":"Penetrating-peptide-mediated non-invasive axitinib delivery for anti-neovascularisation","volume":"347","author":"Huang","year":"2022","journal-title":"J. Contr. Release : Off. J. Contr. Release Soc."},{"issue":"46","key":"10.1016\/j.mtbio.2026.102819_bib26","doi-asserted-by":"crossref","first-page":"14584","DOI":"10.1021\/acs.nanolett.4c02576","article-title":"Reactive oxygen species responsive supramolecular prodrug eyedrops for the treatment of choroidal neovascularization","volume":"24","author":"Xu","year":"2024","journal-title":"Nano Lett."},{"issue":"11","key":"10.1016\/j.mtbio.2026.102819_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202410744","article-title":"Peptide-bound aflibercept eye drops for treatment of neovascular age-related macular degeneration in nonhuman Primates","volume":"12","author":"Fan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.mtbio.2026.102819_bib28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jconrel.2023.12.003","article-title":"MicroRNA-195 liposomes for therapy of Alzheimer's disease","volume":"365","author":"Su","year":"2024","journal-title":"J. Contr. Release : Off. J. Contr. Release Soc."},{"issue":"6","key":"10.1016\/j.mtbio.2026.102819_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12462","article-title":"Milk-derived extracellular vesicles functionalized with anti-tumour necrosis factor-\u03b1 nanobody and anti-microbial peptide alleviate ulcerative colitis in mice","volume":"13","author":"Jing","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.mtbio.2026.102819_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114342","article-title":"Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies","volume":"187","author":"Alshaikh","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.mtbio.2026.102819_bib31","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following Bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"issue":"10432","key":"10.1016\/j.mtbio.2026.102819_bib32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.mtbio.2026.102819_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.mtbio.2026.102819_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.oret.2020.09.024","article-title":"Patient-reported complications after intravitreal injection and their predictive factors","volume":"5","author":"Ramos","year":"2021","journal-title":"Ophthalmol. Retina"},{"issue":"3","key":"10.1016\/j.mtbio.2026.102819_bib35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1128\/CMR.00113-16","article-title":"Bacterial and fungal endophthalmitis","volume":"30","author":"Durand","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"issue":"4","key":"10.1016\/j.mtbio.2026.102819_bib36","article-title":"Rational fusion design inspired by cell-penetrating peptide: SS31\/S-14 G Humanin hybrid peptide with amplified multimodal efficacy and bio-permeability for the treatment of Alzheimer's disease","volume":"19","author":"Qian","year":"2024","journal-title":"Asian J. Pharm. Sci."},{"issue":"44","key":"10.1016\/j.mtbio.2026.102819_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adh1582","article-title":"An immunotherapeutic artificial vitreous body hydrogel to control choroidal melanoma and preserve vision after vitrectomy","volume":"9","author":"Chen","year":"2023","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.mtbio.2026.102819_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000370152","article-title":"Animal eye models for uveal melanoma","volume":"1","author":"Cao","year":"2015","journal-title":"Ocular Oncol. Pathol."}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426000621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426000621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T12:49:54Z","timestamp":1774356594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006426000621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":38,"alternative-id":["S2590006426000621"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.102819","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ROS-responsive transmembrane peptide-antibody conjugate eyedrops for the non-invasive treatment of choroidoretinopathy","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.102819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102819"}}